The FDA has “held” a Summit to survival bar in its review of ivonescimab after an efficacy shortfall in EGFR-mutant non–small cell lung cancer. The move comes after follow-up data that helped address questions about activity in Western patients, according to a BioCentury report. While the updated information clarified some aspects of the trial’s behavior, the primary analysis reportedly did not meet the agency’s expectations for the EGFR-mutant NSCLC population. The situation highlights how endpoint performance thresholds and subgroup effects can drive regulatory timelines. For sponsors, the episode reinforces the need for robust prespecified evidence tied to the FDA’s survival-focused decision criteria, especially in biomarker-defined NSCLC settings.